28 results on '"Cacciola, Emma"'
Search Results
2. Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
3. Thrombosis in Tregs-Induced Thrombocithopenia in Patients with Myelofibrosis
4. Vaccine-Induced Thrombotic Thrombocytopenia: Novelty Testing in the Diagnostic Work-up?
5. Ruxolitinib for the Treatment of Polycythemia Vera: Response on Alternative Dose Versus Standard Dose
6. Increased Thromboxane in Patients with Polycythemia Vera and Thrombosis: Evidence for Aspirin-Unsuppressible Platelet Activation In Vivo
7. Morning Vs Bedtime Aspirin Intake in Patients with Essential Thrombocythemia
8. How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)
9. Aspirin-Platelet Sensitivity in Patients with Polycythemia Vera and Human Platelet Antigen Genotype: Which Are Assays Valid?
10. Aspirin-Platelet Sensitivity in Patients with Essential Thrombocythemia: Role βfibrinogen G-455-a Gene Polymorphism
11. Heterozygosity for JAK2V617F Is a Risk Factor of Developing Post-Polycythemia Vera Myeloofibrosis?
12. Effect Of Heterozygous JAK2 V617F On Thrombotic Risk In Patients With Polycythemia Vera: Measuring The Uncertain
13. Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms
14. Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT)
15. Interleukin-15 Levels in Patients with Essential Thrombocythemia
16. Inflammation and Thrombosis In Essential Thrombocythemia
17. Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia(RIT),
18. Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT)
19. Fibroblast Growth Factor-2 and Lactate Dehydrogenase Levels in Patients with Essential Thrombocythemia Treated with Anagrelide.
20. Quality of Life in Elderly Patients with Essential Thrombocythemia.
21. Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data
22. Phase II–III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial
23. Cytoreductive Combined Therapy in Essential Thrombocythemia Patients: Report of the Registro Italiano Trombocitemia (RIT)
24. JAK2V617F Mutation Status and Thrombosis in Essential Thrombocythemia
25. Efficacy of Anagrelide Compared with Hydroxyurea in Patients with Essential Thrombocythemia.
26. The Registro Italiano Trombocitemie (GIMEMA Project): Preliminary Analysis of the First 801 Enrolled Patients.
27. Tissue Plasminogen Activator (t-PA) and Plasminogen Activator Inhibitor-1 (PAI-1) in Essential Thrombocythemia and Polycythemia Vera and Thrombotic Complications.
28. Inherited Thrombophilias in Essential Thrombocythemia and Polycythemia Vera Are Not an Additional Risk Factor for Thrombosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.